Institute of Liver and Biliary Sciences, India: Acute-On-Chronic Liver Failure trials

The registry lists 42 Acute-On-Chronic Liver Failure studies with Institute of Liver and Biliary Sciences, India as lead sponsor. 17 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2Phase 3 3No phase 37(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.Not yet recruitingNCT07422948Not applicable
• Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled TrialNot yet recruitingNCT07184866Not applicable
• Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)Not yet recruitingNCT07178366Not applicable
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)Not yet recruitingNCT07131540Phase 1
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II TrialNot yet recruitingNCT07131306Phase 2
• National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III TrialNot yet recruitingNCT07075315Phase 3
• Comparison of Blood Products Required Using Two Different ROTEM Cut-offs Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure (ACLF) Patients With Severe CoagulopathyRecruitingNCT06831565Not applicable
• Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.Not yet recruitingNCT06818565Not applicable
• Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal BleedNot yet recruitingNCT06815770Phase 2/3
• Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)Not yet recruitingNCT06808009Not applicable
• Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic ShockNot yet recruitingNCT06556472Not applicable
• To Determine the Predictors of Reversibility for Acute-on-Chronic Liver Failure at 6-months.Not yet recruitingNCT06387160
• Acute hemodynamiC Response To Carvedilol Predicts Survival in ACLF PatientsNot yet recruitingNCT06298656
• An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment ResponseNot yet recruitingNCT06276907Not applicable
• Lactate Kinetics as a Predictor of Survival in ACLF With Septic ShockNot yet recruitingNCT06116305
• Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver FailureNot yet recruitingNCT06069284
• To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.Not yet recruitingNCT06066814
• To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure PatientsStatus unknownNCT05672589Not applicable
• Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.Status unknownNCT05180292Not applicable
• Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver FailureCompletedNCT04983108
• Incidence and Predictors of Bleeding Diathesis Development Due to DIC in Cirrhosis and ACLF Patients Undergoing CRRTStatus unknownNCT04960163
• Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.Status unknownNCT04621812
• Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.Status unknownNCT04474262Not applicable
• Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBVStatus unknownNCT04431375Not applicable
• Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.CompletedNCT04416282Not applicable
• Bowel Colonization With Multi-drug Resistant Bacterial Species in Hospitalized Patients With acute-on Chronic Liver Failure (ACLF), and Its Relationship With Extra-intestinal Infectious Events and Short-term Outcomes.CompletedNCT04383106
• Efficacy and Safety of Hemoperfusion or Plasma Exchange Compared to Standard Medical Therapy in Patients With Acute on Chronic Liver FailureStatus unknownNCT04013113Not applicable
• Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).Status unknownNCT03754400Not applicable
• To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).WithdrawnNCT03162419Not applicable
• To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute PhaseTerminatedNCT02788240Not applicable
• High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver FailureCompletedNCT02719210Not applicable
• To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver FailureCompletedNCT02691533Not applicable
• Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.CompletedNCT02689245Not applicable
• Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal VaricesCompletedNCT02583698Not applicable
• To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver FailureCompletedNCT02573727Not applicable
• Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.CompletedNCT02467348Not applicable
• To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.WithdrawnNCT02465619
• Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.CompletedNCT02321371Not applicable
• Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and SepsisCompletedNCT02307409
• Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).CompletedNCT01946360Not applicable
• Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver FailureCompletedNCT01872767
• Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver FailureCompletedNCT01383460Phase 3